Gynecol Oncol: A Phase II study of eviemos and beva semostina in recurrent ovarian, peritoneal and fallopian tube cancers

Recurrentthe possibility of, fallopian tube and peritoneal cancer senile cancer sourcing it with traditional therapy is limitedPreliminary results from phase I studies of eviemos and bevalo semostasis in late-stage solid tumors suggest that this is a promising combinationThe purpose of this study was to assess the six-month non-progression of everolimus and beveles in recurrent ovarian, peritoneal and fallopian tube cancersSecondary objectives include evaluating efficacy and safetyin this open-label, single-body, Phase II trial, patients were given 10 mg oral ivermes daily, intravenously with 10 mg/kg every 14 days, with a cycle of 28 daysTreatment continues until the disease progresses or adverse events occurresults, 50 patients were includedThe median age is 60.5 years (range 28-82)Forty-six (92%) of the subjects had a medical condition13 (26%) (after correction) had no progress at 6 months (95% CI 16.67-42.71%)One patient had a full response, while 6 patients had partial responses, and 35 patients had the best response to be stablePatients with platinum-sensitive and drug-resistant diseases showed reactions, as did some patients who had previously been exposed to belaval of ceratinIn 25 different patients, 2 level4 and 31 level 3 toxicity were notedThe most common reports of toxicity include oral mucositis, fatigue, diarrhea, high blood pressure, pain, nausea and anorexiaThirty-eight (76%) of the patients withdrew from the study because of the progression of the diseaseUnique molecular characteristics were found in long-term respondersin general, the results showed that the combined use of eviamos and beva meditabyeure did not significantly improve the response compared to the use of bevalo seofid, but further studies of patients with changes in the selected PI3K/mTOR pathway may document their benefits